Diabetic CKD — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Add an SGLT2 inhibitor with sick-day advice
SGLT2 inhibitors reduce CKD progression and cardiovascular events in albuminuric diabetic CKD when eGFR is within licensed and guideline-supported thresholds. Stopping tolerated RAAS blockade would remove an established renal-protective therapy. Steroids and erythropoietin do not treat diabetic albuminuric kidney disease. The pearl is that early eGFR dip after SGLT2 initiation is expected, but a larger or symptomatic decline should prompt review.
Reference: NICE NG203; NICE TA775/TA942; KDIGO 2024 CKD Guideline